Accueil   Diary - News   All news Theranexus and BBDF announce to develop and market Batten disease drug candidate BBDF 101

Theranexus and BBDF announce to develop and market Batten disease drug candidate BBDF 101

 

  • BBDF has funded research to identify and validate BBDF 101 for the treatment of juvenile Batten disease.
  • Theranexus and BBDF will jointly lead the clinical development program in the US to secure regulatory approval for the product
  • Theranexus will have an exclusive worldwide license for commercial use of the product

 

Lyon, 27 June 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, is pleased to announce the signing of an agreement in principle (term sheet) with Beyond Batten Disease Foundation (BBDF) to lead the clinical development program aimed at securing approval and commercialization for drug candidate BBDF 101 for Batten disease. The agreement gives Theranexus a six-month exclusivity period to reach a final agreement.

 

Read the press release